Table 2. General management of immune-related adverse events caused by immune checkpoint inhibitors (55).

Severity CTCAE grade	Ambulatory vs. inpatient care	Corticosteroids	Other immunosuppressive drugs	ICI
1	Ambulatory	Not recommended	Not recommended	Continue
2	Ambulatory	Topical or systemic steroids oral 0.5–1 mg/kg/day	Not recommended	Suspended temporally*
3	Hospitalization	Systemic steroids Oral or IV 1–2 mg/kg/day for 3 days then reduce to 1 mg/kg/day	To be considered for patients with unresolved symptoms after 3–5 days of steroid course Organ Specialist referral advised	Suspend and discuss resumption based on risk/benefit ratio with patient
4	Hospitalization consider intensive care unit	Systemic steroids iv methylprednisolone 1–2 mg/kg/day for 3 days then reduce to 1 mg/kg/day	To be considered for patients with unresolved symptoms after 3–5 days of steroid course; organ specialist referral advised	Discontinue permanently

*, outside skin or endocrine disorders where immunotherapy can be maintained. ICI, immune checkpoint inhibitors.